The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
Abstract
Summary: Antidopaminergic gastrointestinal prokinetics (bromopride, clebopride, domperidone, levosulpiride and metoclopramide) have been exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis. The prokinetic effect of these drugs is mediated through the blockade of enteric (neuronal and muscular) inhibitory D 2 receptors. The pharmacological profiles of the marketed compounds differ in terms of their molecular structure, affinity at D 2 receptors, ability to interact with other receptor systems [5‐hydroxytryptamine‐3 (5‐HT 3) and 5‐HT 4 receptors for metoclopramide; 5‐HT 4 receptors for levosulpiride) and ability to permeate the blood–brain barrier (compared with the other compounds, domperidone does not easily cross the barrier). It has been suggested that the serotonergic (5‐HT 4) component of some antidopaminergic prokinetics may enhance their therapeutic efficacy in gastrointestinal disorders, such as functional dyspepsia and diabetic gastroparesis. The antagonism of central D 2 receptors may lead to both therapeutic (e.g. anti‐emetic effect due to D 2 receptor blockade in the area postrema) and adverse (including hyperprolactinaemia and extrapyramidal dystonic reactions) effects. As the pituitary (as well as the area postrema) is outside the blood–brain barrier, hyperprolactinaemia is a side‐effect occurring with all antidopaminergic prokinetics, although to different extents. Extrapyramidal reactions are most commonly observed with compounds crossing the blood–brain barrier, although with some differences amongst the various agents. Prokinetics with a high dissociation constant compared with that of dopamine at the D 2 receptor (i.e. compounds that bind loosely to D 2 receptors in the nigrostriatal pathway) elicit fewer extrapyramidal signs and symptoms. A knowledge of central and peripheral D 2 receptor pharmacology can help the clinician to choose between the antidopaminergic prokinetics to obtain a more favourable risk/benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pharmacological interventions for non-ulcer dyspepsia
Moayyedi, P., Soo, S., Deeks, J. J., DELANEY, B., Innes, M., & Forman, D. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001960 · Cited by 114
RetractedPharmacological interventions for non-ulcer dyspepsia
Moayyedi, P., Shelly, S., Deeks, J. J., Delaney, B., Innes, M., & Forman, D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001960.pub3 · Cited by 99
RetractedSokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Functional Gastroduodenal Disorders
Tack, J., Talley, N. J., Camilleri, M., Holtmann, G., Hu, P., Malagelada, J.-R., & Stanghellini, V. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.059 · Cited by 2,418
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
Dopamine receptor pharmacology
Seeman, P., & Van Tol, H. H. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 956
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Structure and function of dopamine receptors
Vallone, D., Picetti, R., & Borrelli, E. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00063-9 · Cited by 818
Functional gastroduodenal disorders
Talley, N. J., Stanghellini, V, Heading, R. C., Koch, K. L., Malagelada, J. R., & Tytgat, G. N. J. (1999) · Gut · doi:10.1136/gut.45.2008.ii37 · Cited by 746
Catecholamine metabolism: basic aspects and clinical significance.
Kopin, I. J. (1985) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06859-0 · Cited by 582
Cited by
Parkinson's Disease and Parkinsonism
Hayes, M. T. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.03.001 · Cited by 823
Shin, H.-W., & Chung, S. J. (2012) · Journal of Clinical Neurology · doi:10.3988/jcn.2012.8.1.15 · Cited by 354
Review article: metoclopramide and tardive dyskinesia
RAO, A. S., & CAMILLERI, M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04189.x · Cited by 316
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Tack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Metadata
- Authors
- Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R., & De Ponti, F.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 19
- Issue
- 4
- Pages
- 379-390
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2017815761
- Cited by
- 291
- References
- 69
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.01867.x
- The paper
- Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R., & De Ponti, F. (2004). Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.01867.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.